October 26, 2016 3:49 AM ET


Company Overview of Novelos Therapeutics, Inc.

Company Overview

As of April 8, 2011, Novelos Therapeutics, Inc. was acquired by Cellectar, Inc., in a reverse merger transaction. Novelos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis in the United States. Its development product line primarily includes NOV-002, a phase II injectable small-molecule compound, which acts as a chemopotentiator and a chemoprotectant and that is being developed for use in combination with standard of care chemotherapies for the treatment of solid tumors. The NOV-002 is also being developed and is in phase II clinical trial to treat early-stage breast cancer...

One Gateway Center

Suite 504

Newton, MA 02458

United States

Founded in 1996

12 Employees





Key Executives for Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novelos Therapeutics, Inc., please visit www.novelos.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.